Business Description
Emcure Pharmaceuticals Ltd
ISIN : INE168P01015
Total Employee Number:
11,474Compare
Compare
Traded in other countries / regions
544210.India Index Membership
NIFTY 500 IPO Date
2024-07-10Description
Emcure Pharmaceuticals Ltd an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several therapeutic areas. Its portfolio includes orals including solids, liquid orals and dry syrup/suspensions., injectables such as vials and pre-filled syringes, and forms such as lyophilized & liquid and biotherapeutics. The company operates in Derma, Women's Health, Cardiovascular, Neurology, Oncology, Vaccines, and Anti-infectives. Geographically, it operates in India, Europe, Canada, Vietnam, Dubai, and Other Countries.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.14 | |||||
Equity-to-Asset | 0.52 | |||||
Debt-to-Equity | 0.31 | |||||
Debt-to-EBITDA | 0.82 | |||||
Interest Coverage | 9.56 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 6.04 | |||||
Beneish M-Score | -2.16 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14 | |||||
3-Year EBITDA Growth Rate | 14.6 | |||||
3-Year EPS without NRI Growth Rate | 19.2 | |||||
3-Year FCF Growth Rate | 3.2 | |||||
3-Year Book Growth Rate | 25.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 20.01 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 11.92 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 60.29 | |||||
9-Day RSI | 59.65 | |||||
14-Day RSI | 59.03 | |||||
3-1 Month Momentum % | 12.39 | |||||
6-1 Month Momentum % | 20.21 | |||||
12-1 Month Momentum % | 29.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.43 | |||||
Quick Ratio | 0.82 | |||||
Cash Ratio | 0.06 | |||||
Days Inventory | 220.72 | |||||
Days Sales Outstanding | 90.75 | |||||
Days Payable | 166.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.16 | |||||
Dividend Payout Ratio | 0.06 | |||||
Forward Dividend Yield % | 0.16 | |||||
5-Year Yield-on-Cost % | 0.16 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | -1.28 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 60.27 | |||||
Operating Margin % | 14.92 | |||||
Net Margin % | 10.04 | |||||
EBITDA Margin % | 20.06 | |||||
FCF Margin % | 4.3 | |||||
OCF Margin % | 10.25 | |||||
ROE % | 19.61 | |||||
ROA % | 10.18 | |||||
ROIC % | 14.7 | |||||
3-Year ROIIC % | 12.13 | |||||
ROC (Joel Greenblatt) % | 29.69 | |||||
ROCE % | 25.29 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 38.6 | |||||
Forward PE Ratio | 30.86 | |||||
PE Ratio without NRI | 36.46 | |||||
Price-to-Owner-Earnings | 50.95 | |||||
PEG Ratio | 6.63 | |||||
PS Ratio | 3.87 | |||||
PB Ratio | 7.19 | |||||
Price-to-Tangible-Book | 9.27 | |||||
Price-to-Free-Cash-Flow | 90.1 | |||||
Price-to-Operating-Cash-Flow | 37.79 | |||||
EV-to-EBIT | 25.87 | |||||
EV-to-EBITDA | 20.05 | |||||
EV-to-Revenue | 4.03 | |||||
EV-to-FCF | 88.84 | |||||
Price-to-Peter-Lynch-Fair-Value | 6.61 | |||||
Price-to-Graham-Number | 3.88 | |||||
| Price-to-Net-Current-Asset-Value | 37.57 | |||||
Earnings Yield (Greenblatt) % | 3.86 | |||||
FCF Yield % | 1.11 | |||||
Forward Rate of Return (Yacktman) % | 6.99 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Emcure Pharmaceuticals Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 92,035.4 | ||
| EPS (TTM) (₹) | 48.77 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 19.47 | ||
| 14-Day RSI | 59.03 | ||
| 14-Day ATR (₹) | 55.452452 | ||
| 20-Day SMA (₹) | 1836.435 | ||
| 12-1 Month Momentum % | 29.09 | ||
| 52-Week Range (₹) | 1260 - 1944 | ||
| Shares Outstanding (Mil) | 189.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Emcure Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Emcure Pharmaceuticals Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 3.000000 Cash Dividend | 2025-08-14 | 1,453.80 (+3.22%) |
Show
Entries
Emcure Pharmaceuticals Ltd Frequently Asked Questions
What is Emcure Pharmaceuticals Ltd(NSE:EMCURE)'s stock price today?
The current price of NSE:EMCURE is ₹1881.00. The 52 week high of NSE:EMCURE is ₹1944.00 and 52 week low is ₹1260.00.
When is next earnings date of Emcure Pharmaceuticals Ltd(NSE:EMCURE)?
The next earnings date of Emcure Pharmaceuticals Ltd(NSE:EMCURE) is .
Does Emcure Pharmaceuticals Ltd(NSE:EMCURE) pay dividends? If so, how much?
The Dividend Yield %  of Emcure Pharmaceuticals Ltd(NSE:EMCURE) is 0.16% (As of Today), Highest Dividend Payout Ratio of Emcure Pharmaceuticals Ltd(NSE:EMCURE) was 0.06. The lowest was 0.06. And the median was 0.06. The  Forward Dividend Yield % of Emcure Pharmaceuticals Ltd(NSE:EMCURE) is 0.16%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Emcure Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers